Search
revacept
Contraindications:
- addition to currently recommended antithrombotic therapy in the setting of percutaneous coronary intervention in patients with stable ischemic heart disease does not reduce the incidence of myocardi
Mechanism of action:
- platelet glycoprotein VI antagonist
Interactions
drug adverse effects of antiplatelet agents
General
antiplatelet agent
receptor antagonist
References
- Schupke S, Hein-Rothweiler R, Mayer K et al ISAR-PLASTER-Trial Investigators.
Revacept, a Novel Inhibitor of Platelet Adhesion, in Patients Undergoing
Elective PCI-Design and Rationale of the Randomized ISAR-PLASTER Trial.
Thromb Haemost. 2019 Sep;119(9):1539-1545.
PMID: 31226721
- Mayer K, Hein-Rothweiler R, Schupke S et al
Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist
to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary
Intervention for Stable Ischemic Heart DiseaseThe Randomized, Double-blind,
Placebo-Controlled ISAR-PLASTER Phase 2 Trial.
JAMA Cardiol. Published online March 31, 2021
PMID: 33787834
https://jamanetwork.com/journals/jamacardiology/fullarticle/2777812